HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].

Abstract
Pancreatitis occurs in up to 7% of patients infected with human immunodeficiency virus who are treated with standard doses of didanosine. Tenofovir disoproxil fumarate increases the plasma levels of didanosine and, thus, the combination of these agents may increase the risk of pancreatitis. Four cases of pancreatitis that occurred during administration of this drug combination are examined, including 1 that resulted in death.
AuthorsJennifer N Blanchard, Michael Wohlfeiler, Albert Canas, Kevin King, J Tyler Lonergan
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 37 Issue 5 Pg. e57-62 (Sep 01 2003) ISSN: 1537-6591 [Electronic] United States
PMID12942419 (Publication Type: Case Reports, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Organophosphonates
  • Organophosphorus Compounds
  • Tenofovir
  • Adenine
  • Didanosine
Topics
  • Adenine (adverse effects, analogs & derivatives, therapeutic use)
  • Adult
  • Didanosine (adverse effects, blood, therapeutic use)
  • Drug Interactions
  • Fatal Outcome
  • Female
  • HIV Infections (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Organophosphonates
  • Organophosphorus Compounds (adverse effects, therapeutic use)
  • Pancreatitis (chemically induced, drug therapy)
  • Tenofovir

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: